Abstract
465
Objectives Currently, thrombus imaging relies on different modalities depending on the vascular territory (e.g. ultrasonography, CT, etc). Considering the limitations with respect to thrombus location a molecular imaging technique to visualize thrombus in the context of vascular anatomy using PET-CT or SPECT-CT and whole body imaging would be a valuable tool. We recently characterized 4 probes labeled with 64Cu and Al18F for thrombus imaging.(1) Here we extend our findings to 68Ga PET and 111In SPECT, and use multimodal imaging to demonstrate the in vivo specificity of these probes for fibrin and thrombus.
Methods Probes were synthesized by conjugation of a fibrin-binding peptide to NODAGA or DOTA followed by labeling with 68Ga (FBP14) or 111In (FBP15), respectively. SPECT/PET imaging properties, biodistribution, pharmacokinetics and stability were assessed in two rat models of carotid thrombosis (crush- and FeCl3-injury). Target specificity was further evaluated with SPECT/PET-CT imaging by comparing targeted FBP14 and FBP15 to an isomeric untargeted 64Cu-D-Cys-FBP8 and by co-localization of the 68Ga PET or 111In SPECT signal to the 125I SPECT signal of thrombus formed by incorporation of 125I-fibrinogen.
Results FBP14 and FBP15 showed high in vitro affinity for fibrin (530 and 600 nM), and high thrombus uptake (~0.9% ID/g), favorable biodistribution and fast blood clearance (t1/2 = 8-15 min) in rats. Thrombus uptake was the second highest, just after the kidneys (2-4% ID/g). Target specificity studies by multimodal SPECT/PET-CT imaging showed that focal signal of 68Ga-FBP14 and 111In-FBP15 co-localizes with the preformed 125I-labeled clot, however the non-binding derivative 64Cu-D-Cys-FBP8 does not co-localize with the hot clot (Figure).
Conclusions FBP14 and FBP15 have high target affinity and specificity for fibrin but distinctive physical and imaging properties that make them suitable for different medical applications for thrombus detection.
Research Support HL109448 from the National Heart, Lung, and Blood Institute (Dr. Caravan).